Replies to post #130476 on Biotech Values

[DewDiligence]

Side effects aside, this data would appear to back up ACHN's prior assertions (item 3 of #msg-66070779 ) about an NS5A + PI potentially being enough for genotype 1b patients.

It’s consistent with such a notion, but we’ll need more patients and full-fledged SVR data (rather than SVR12) to say whether this idea has merit. There’s also the question of whether this regimen might be better suited for Japanese patients than for patients of other ethnic groups.